Methods for diagnosing systemic lupus erythematosus
View Patent ↗The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus.
1. A method for treating Systemic Lupus Erythematosus (SLE) in a human subject identified as negative for SLE based on double stranded DNA antibody (anti-dsDNA) marker levels, the method comprising
(a) determining a level of: erythrocyte C4d (EC4d) marker in a first blood sample from a subject and B-cell C4d (BC4d) marker in a second blood sample from the subject; and anti-MCV antibody marker in a third blood sample from the subject, wherein the first, second, and third biological samples may be the same or different
(b) calculating an SLE risk score by adjusting the level of the markers by one or more transformation analyses, wherein the one or more transformation analyses comprises logistic regression analysis, and wherein the logistic regression analysis comprises
(i) adjusting the level of the markers by an appropriate weighting coefficient to produce a weighted score for each marker, and
(ii) combining the weighted score for each marker to generate the SLE risk score;
(c) comparing the SLE risk score to one or more of a standard that is a pre-determined SLE risk score derived from a population of subjects afflicted with SLE, or a pre-determined SLE risk score derived from a population of subjects afflicted with a non-SLE autoimmune disease
(d) identifying the subject as likely to have SLE based on the SLE risk score comparison to the standard, wherein the SLE risk score is
(i) increased compared to the pre-determined SLE risk score derived from a population of subjects afflicted with a non-SLE autoimmune disease; or
(ii) equivalent to the pre-determined SLE risk score derived from a population of subjects afflicted with SLE; and
(e) treating the subject likely to have SLE with an amount effective to treat SLE of one or more therapeutic selected from the group consisting of cyclophosphamide, corticosteroids, mycophenolate, methotrextate, azathiopurine, leflunomide, belimumab, plaquenil and hydroxychloroquine.
2. The method of claim 1 , further comprising determining a level of an anti-nuclear antibody (ANA) marker in the third blood sample from the subject, wherein calculating the SLE risk score further comprises adjusting the level of the ANA marker by one or more transformation analyses.
3. The method of claim 1 , wherein determining the BC4d marker level comprises determining the level of BC4d on the surface of B lymphocytes and determining the EC4d marker level comprises determining the level of EC4d on the surface of erythrocytes.
4. The method of claim 1 , wherein the second blood sample is a cell or tissue extract comprising B lymphocytes, and the first blood sample is a cell or tissue extract comprising erythrocytes.
5. The method of claim 1 , wherein the level of the BC4d marker and the level of the EC4d marker is determined using an antibody specific for C4d.
6. The method of claim 1 , wherein the first blood sample is a cell or tissue extract comprising erythrocytes and the second blood sample is a cell or tissue extract comprising B lymphocytes.